Schoenbrun will retire from the organization in December after coming out of retirement to serve as the interim executive director for OGS in 2022.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

Focusing on the care of patients with MGD, Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO, provide key takeaways on treatment practices.

Dry eye experts provide comprehensive insights on the role of in-office procedural therapies.

The quality of options for patients has improved in recent years.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

From surgeon to mentor: Smith fuels her commitment to improving glaucoma care by training future ophthalmologists.

Catch up on what happened in optometry during the week of July 15-July 19.

TEAM-OGS gives practices more fundraising opportunities to end preventable blindness and vision impairment globally throughout the year.

Removing drops improves adherence and comfort for most patients.

Organization corresponding secretary Babirekere Bakama weighs in on her favorite learning opportunities at this year’s NOA Convention.

An introduction to cerebral visual impairment.

Utilizing artificial intelligence may provide feasibility assessments, data-driven protocol design, and cost reduction opportunities.

Cofounders Camille F. Cohen, OD, FAAO, and Janis James, OD, FAAO discuss what the organization has been up to at the National Optometric Association Convention.

Selina McGee, OD, FAAO, discusses the role of cyclosporine ophthalmic solution (VEVYE) in the treatment of dry eye disease.

Experts provide clinical insights on the first FDA-approved treatment for evaporative dry eye, perfluorohexyloctane ophthalmic solution (MEIBO).